Search

Your search keyword '"Cluzeau T"' showing total 283 results
Start Over Author "Cluzeau T"
283 results on '"Cluzeau T"'

1. Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

Author

Kubasch, A. S., Peterlin, P., Cluzeau, T., Götze, K. S., Sockel, K., Teipel, R., Jentzsch, M., Attalah, H., Sebert, M., Chermat, F., Gloaguen, S., Puttrich, M., Cross, M., Schneider, M., Kayser, S., Schipp, D., Giagounidis, A., Tirado-Gonzalez, I., Descot, A., van de Loosdrecht, A., Weigert, A., Metzeler, K. H., Fenaux, P., Medyouf, H., Platzbecker, U., and Ades, L.

Published
2023
Full Text
View/download PDF

4. Effective Algebraic Analysis Approach to Linear Systems over Ore Algebras

Author

Cluzeau, T., Koutschan, C., Quadrat, A., Tõnso, M., Niculescu, Silviu-Iulian, Editor-in-Chief, Atay, Fatihcan M., Advisory Editor, Bellen, Alfredo, Advisory Editor, Chen, Jie, Advisory Editor, Gu, Keqin, Advisory Editor, Krauskopf, Bernd, Advisory Editor, Michiels, Wim, Advisory Editor, Özbay, Hitay, Advisory Editor, Rasvan, Vladimir, Advisory Editor, Stepan, Gabor, Advisory Editor, Zerz, Eva, Advisory Editor, Zhong, Qing-Chang, Advisory Editor, and Quadrat, Alban, editor

Published
2020
Full Text
View/download PDF

6. EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL

Author

Garcia-Manero, G, Platzbecker, U, Santini, V, Zeidan, A, Fenaux, P, Komrokji, R, Shortt, J, Valcarcel, D, Jonasova, A, Dimicoli-Salazar, S, Tiong, IS, Lin, C-C, Li, J, Zhang, J, Giuseppi, AC, Kreitz, S, Pozharskaya, V, Keeperman, K, Rose, S, Prebet, T, Degulys, A, Paolini, S, Cluzeau, T, Porta, MD, Garcia-Manero, G, Platzbecker, U, Santini, V, Zeidan, A, Fenaux, P, Komrokji, R, Shortt, J, Valcarcel, D, Jonasova, A, Dimicoli-Salazar, S, Tiong, IS, Lin, C-C, Li, J, Zhang, J, Giuseppi, AC, Kreitz, S, Pozharskaya, V, Keeperman, K, Rose, S, Prebet, T, Degulys, A, Paolini, S, Cluzeau, T, and Porta, MD

Published
2024

7. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Author

Ruggeri, A, de Wreede, L, Muller, C, Crivello, P, Bonneville, E, Petersdorf, E, Socie, G, Dubois, V, Niittyvuopio, R, Perasaari, J, Yakoub-Agha, I, Cornelissen, J, Wieten, L, Gedde-Dahl, T, Forcade, E, Crawley, C, Marsh, S, Gandemer, V, Tholouli, E, Bulabois, C, Huynh, A, Choi, G, Deconinck, E, Itala-Remes, M, Lenhoff, S, Bengtsson, M, Johansson, J, van Gorkom, G, Hoogenboom, J, Vago, L, Rocha, V, Bonini, C, Chabannon, C, Fleischhauer, K, Clausen, J, Holter, W, Kalhs, P, Beguin, Y, Bron, D, Deeren, D, Lung, W, Kerre, T, Poire, X, Selleslag, D, Schroyens, W, Jindra, P, Mayer, J, Vydra, J, Zak, P, Nielsen, B, Sengeloev, H, Kaare, A, Partanen, A, Bay, J, Bertrand, Y, Blaise, D, Bourhis, J, Chevallier, P, Cluzeau, T, Damaj, G, Fegueux, N, Guyotat, D, Hunault-Berger, M, Labussiere-Wallet, H, Leleu, X, Lioure, B, Maury, S, Michel, G, Mohty, M, Rubio, M, Tilly, H, Turlure, P, Bethge, W, Casper, J, Einsele, H, Ganser, A, Kroger, N, Martin, S, Platzbecker, U, Reinhardt, C, Schafer-Eckart, K, Thurner, L, Valerius, T, Wulf, G, Karakasis, D, Spyridonidis, A, Hauser, P, Remenyi, P, Reykdal, S, Mousavi, A, Angelucci, E, Arcese, W, Benedetti, F, Bernasconi, P, Biondi, A, Bonifazi, F, Carella, A, Carluccio, P, Casini, M, Cavanna, L, Ciceri, F, Cimino, G, Corradini, P, Fanin, R, Galieni, P, Grillo, G, Iori, A, La Nasa, G, Locatelli, F, Marotta, G, Martino, M, Mazza, P, Mordini, N, Musso, M, Olivieri, A, Pavone, V, Pane, F, Petrini, M, Pioltelli, P, Rambaldi, A, Ruggeri, M, Saccardi, R, Santarone, S, Scime, R, Sica, S, Tarella, C, Velardi, A, Visani, G, Zecca, M, Tanase, A, Kulagin, A, Savchenko, V, Lopez, C, Amor, A, Lopez, J, Caballero, D, Duarte, R, Cascon, M, Porras, R, Perez-Simon, J, Rovira, M, Sanz, J, Carrete, J, Cammenga, J, Isaksson, C, Mielke, S, Chalandon, Y, Passweg, J, Schanz, U, Meijer, E, Kuball, J, Veelken, J, Apperley, J, Bloor, A, Byrne, J, Carpenter, B, Clark, A, Collin, M, Craddock, C, Gibson, B, Khan, A, Martin, M, Medd, P, Nicholson, E, Orchard, K, Patel, A, Peniket, A, Potter, V, Snowden, J, Wilson, K, Ruggeri A., de Wreede L. C., Muller C. R., Crivello P., Bonneville E. F., Petersdorf E. W., Socie G., Dubois V., Niittyvuopio R., Perasaari J., Yakoub-Agha I., Cornelissen J. J., Wieten L., Gedde-Dahl T., Forcade E., Crawley C. R., Marsh S. G. E., Gandemer V., Tholouli E., Bulabois C. -E., Huynh A., Choi G., Deconinck E., Itala-Remes M., Lenhoff S., Bengtsson M., Johansson J. -E., van Gorkom G., Hoogenboom J. D., Vago L., Rocha V., Bonini C., Chabannon C., Fleischhauer K., Clausen J., Holter W., Kalhs P., Beguin Y., Bron D., Deeren D., Lung W. K., Kerre T., Poire X., Selleslag D., Schroyens W., Jindra P., Mayer J., Vydra J., Zak P., Nielsen B., Sengeloev H., Kaare A., Partanen A., Bay J., Bertrand Y., Blaise D., Bourhis J. H., Chevallier P., Cluzeau T., Damaj G., Fegueux N., Guyotat D., Hunault-Berger M., Labussiere-Wallet H., Leleu X., Lioure B., Maury S., Michel G., Mohty M., Rubio M. T., Tilly H., Turlure P., Bethge W., Casper J., Einsele H., Ganser A., Kroger N., Martin S., Platzbecker U., Reinhardt C., Schafer-Eckart K., Thurner L., Valerius T., Wulf G. G., Karakasis D., Spyridonidis A., Hauser P., Remenyi P., Reykdal S., Mousavi A., Angelucci E., Arcese W., Benedetti F., Bernasconi P., Biondi A., Bonifazi F., Carella A. M., Carluccio P., Casini M., Cavanna L., Ciceri F., Cimino G., Corradini P., Fanin R., Galieni P., Grillo G., Iori A. P., La Nasa G., Locatelli F., Marotta G., Martino M., Mazza P., Mordini N., Musso M., Olivieri A., Pavone V., Pane F., Petrini M., Pioltelli P., Rambaldi A., Ruggeri M., Saccardi R., Santarone S., Scime R., Sica S., Tarella C., Velardi A., Visani G., Zecca M., Tanase A., Kulagin A., Savchenko V., Lopez C. A., Amor A. A., Lopez J. L. B., Caballero D., Duarte R., Cascon M. J. P., Porras R. P., Perez-Simon J. A., Rovira M., Sanz J., Carrete J. P. T., Cammenga J., Isaksson C., Mielke S., Chalandon Y., Passweg J., Schanz U., Meijer E., Kuball J., Veelken J. H., Apperley J., Bloor A., Byrne J., Carpenter B., Clark A., Collin M., Craddock C., Gibson B. E., Khan A., Martin M., Medd P., Nicholson E., Orchard K., Patel A., Peniket A., Potter V., Snowden J., Wilson K. M. O., Ruggeri, A, de Wreede, L, Muller, C, Crivello, P, Bonneville, E, Petersdorf, E, Socie, G, Dubois, V, Niittyvuopio, R, Perasaari, J, Yakoub-Agha, I, Cornelissen, J, Wieten, L, Gedde-Dahl, T, Forcade, E, Crawley, C, Marsh, S, Gandemer, V, Tholouli, E, Bulabois, C, Huynh, A, Choi, G, Deconinck, E, Itala-Remes, M, Lenhoff, S, Bengtsson, M, Johansson, J, van Gorkom, G, Hoogenboom, J, Vago, L, Rocha, V, Bonini, C, Chabannon, C, Fleischhauer, K, Clausen, J, Holter, W, Kalhs, P, Beguin, Y, Bron, D, Deeren, D, Lung, W, Kerre, T, Poire, X, Selleslag, D, Schroyens, W, Jindra, P, Mayer, J, Vydra, J, Zak, P, Nielsen, B, Sengeloev, H, Kaare, A, Partanen, A, Bay, J, Bertrand, Y, Blaise, D, Bourhis, J, Chevallier, P, Cluzeau, T, Damaj, G, Fegueux, N, Guyotat, D, Hunault-Berger, M, Labussiere-Wallet, H, Leleu, X, Lioure, B, Maury, S, Michel, G, Mohty, M, Rubio, M, Tilly, H, Turlure, P, Bethge, W, Casper, J, Einsele, H, Ganser, A, Kroger, N, Martin, S, Platzbecker, U, Reinhardt, C, Schafer-Eckart, K, Thurner, L, Valerius, T, Wulf, G, Karakasis, D, Spyridonidis, A, Hauser, P, Remenyi, P, Reykdal, S, Mousavi, A, Angelucci, E, Arcese, W, Benedetti, F, Bernasconi, P, Biondi, A, Bonifazi, F, Carella, A, Carluccio, P, Casini, M, Cavanna, L, Ciceri, F, Cimino, G, Corradini, P, Fanin, R, Galieni, P, Grillo, G, Iori, A, La Nasa, G, Locatelli, F, Marotta, G, Martino, M, Mazza, P, Mordini, N, Musso, M, Olivieri, A, Pavone, V, Pane, F, Petrini, M, Pioltelli, P, Rambaldi, A, Ruggeri, M, Saccardi, R, Santarone, S, Scime, R, Sica, S, Tarella, C, Velardi, A, Visani, G, Zecca, M, Tanase, A, Kulagin, A, Savchenko, V, Lopez, C, Amor, A, Lopez, J, Caballero, D, Duarte, R, Cascon, M, Porras, R, Perez-Simon, J, Rovira, M, Sanz, J, Carrete, J, Cammenga, J, Isaksson, C, Mielke, S, Chalandon, Y, Passweg, J, Schanz, U, Meijer, E, Kuball, J, Veelken, J, Apperley, J, Bloor, A, Byrne, J, Carpenter, B, Clark, A, Collin, M, Craddock, C, Gibson, B, Khan, A, Martin, M, Medd, P, Nicholson, E, Orchard, K, Patel, A, Peniket, A, Potter, V, Snowden, J, Wilson, K, Ruggeri A., de Wreede L. C., Muller C. R., Crivello P., Bonneville E. F., Petersdorf E. W., Socie G., Dubois V., Niittyvuopio R., Perasaari J., Yakoub-Agha I., Cornelissen J. J., Wieten L., Gedde-Dahl T., Forcade E., Crawley C. R., Marsh S. G. E., Gandemer V., Tholouli E., Bulabois C. -E., Huynh A., Choi G., Deconinck E., Itala-Remes M., Lenhoff S., Bengtsson M., Johansson J. -E., van Gorkom G., Hoogenboom J. D., Vago L., Rocha V., Bonini C., Chabannon C., Fleischhauer K., Clausen J., Holter W., Kalhs P., Beguin Y., Bron D., Deeren D., Lung W. K., Kerre T., Poire X., Selleslag D., Schroyens W., Jindra P., Mayer J., Vydra J., Zak P., Nielsen B., Sengeloev H., Kaare A., Partanen A., Bay J., Bertrand Y., Blaise D., Bourhis J. H., Chevallier P., Cluzeau T., Damaj G., Fegueux N., Guyotat D., Hunault-Berger M., Labussiere-Wallet H., Leleu X., Lioure B., Maury S., Michel G., Mohty M., Rubio M. T., Tilly H., Turlure P., Bethge W., Casper J., Einsele H., Ganser A., Kroger N., Martin S., Platzbecker U., Reinhardt C., Schafer-Eckart K., Thurner L., Valerius T., Wulf G. G., Karakasis D., Spyridonidis A., Hauser P., Remenyi P., Reykdal S., Mousavi A., Angelucci E., Arcese W., Benedetti F., Bernasconi P., Biondi A., Bonifazi F., Carella A. M., Carluccio P., Casini M., Cavanna L., Ciceri F., Cimino G., Corradini P., Fanin R., Galieni P., Grillo G., Iori A. P., La Nasa G., Locatelli F., Marotta G., Martino M., Mazza P., Mordini N., Musso M., Olivieri A., Pavone V., Pane F., Petrini M., Pioltelli P., Rambaldi A., Ruggeri M., Saccardi R., Santarone S., Scime R., Sica S., Tarella C., Velardi A., Visani G., Zecca M., Tanase A., Kulagin A., Savchenko V., Lopez C. A., Amor A. A., Lopez J. L. B., Caballero D., Duarte R., Cascon M. J. P., Porras R. P., Perez-Simon J. A., Rovira M., Sanz J., Carrete J. P. T., Cammenga J., Isaksson C., Mielke S., Chalandon Y., Passweg J., Schanz U., Meijer E., Kuball J., Veelken J. H., Apperley J., Bloor A., Byrne J., Carpenter B., Clark A., Collin M., Craddock C., Gibson B. E., Khan A., Martin M., Medd P., Nicholson E., Orchard K., Patel A., Peniket A., Potter V., Snowden J., and Wilson K. M. O.

Published
2023

11. Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION

Author

Rombaut, D., primary, Lefevre, C., additional, Farhat, B., additional, Bondu, S., additional, Letessier, A., additional, Lesieur-Pasquier, A., additional, Castillo-Guzman, D., additional, Leduc, M., additional, Hartono, S., additional, Chesnais, V., additional, Mangione, R., additional, Boussaid, I., additional, Houy, A., additional, Bouscary, D., additional, Willems, L., additional, Chapuis, N., additional, Kosmider, O., additional, Park, S., additional, Raynaud, S., additional, Cluzeau, T., additional, Clappier, E., additional, Fenaux, P., additional, Ades, L., additional, Margueron, R., additional, Wassef, M., additional, Alsafadi, S., additional, Solary, E., additional, Constantinou, A., additional, Stern, M.-H., additional, Palancade, B., additional, Droin, N., additional, Miotto, B., additional, Chédin, F., additional, and Fontenay, M., additional

Published
2023
Full Text
View/download PDF

12. Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases

Author

Zakine, Ève, primary, Papageorgiou, Loula, additional, Bourguiba, Rim, additional, Mekinian, Arsène, additional, Terrier, Benjamin, additional, Kosmider, Olivier, additional, Hirsch, Pierre, additional, Jachiet, Marie, additional, Audia, Sylvain, additional, Ardois, Samuel, additional, Adélaïde, Léopold, additional, Bigot, Adrien, additional, Duriez, Paul, additional, Emile, Jean-François, additional, Lazaro, Estibaliz, additional, Fayard, Damien, additional, Galland, Joris, additional, Hié, Miguel, additional, Humbert, Sébastien, additional, Jean, Alexis, additional, Kostine, Marie, additional, Lacombe, Valentin, additional, Le Guenno, Guillaume, additional, Lobbes, Hervé, additional, Magy-Bertrand, Nadine, additional, Marianetti-Guingel, Paola, additional, Mathian, Alexis, additional, Outh, Rodérau, additional, Saillard, Clémence, additional, Samson, Maxime, additional, Vial, Guillaume, additional, Bouaziz, Jean-David, additional, Moguelet, Philippe, additional, Chasset, François, additional, Amoura, Z., additional, Aouba, A., additional, Arnaud, C., additional, Audemard-Verger, A., additional, Bachmeyer, C., additional, Bienvenu, B., additional, Biscay, P., additional, Borlot, F., additional, Bouillet, L., additional, Boursier, G., additional, Carrat, F., additional, Cluzeau, T., additional, Comont, T., additional, Constantin, A., additional, de Sainte Marie, B., additional, Deligny, C., additional, Dieval, C., additional, Duroyon, E., additional, Ebbo, M., additional, Fain, O., additional, Faucher, B., additional, Fenaux, P., additional, Georgin-Lavialle, S., additional, Gerfaud-Valentin, M., additional, Graveleau, J., additional, Guedon, A.F., additional, Hanslik, T., additional, Heiblig, M., additional, Jachiet, V., additional, Jamilloux, Y., additional, Jeannel, J., additional, Larue, M., additional, Le Pelletier, F., additional, Liozon, E., additional, Meyer, A., additional, Moulinet, T., additional, Pha, M., additional, Rossignol, J., additional, Roux, M., additional, Roux-Sauvat, M., additional, Sailler, L., additional, Sarrabay, G., additional, Sebert, M., additional, Servettaz, A., additional, Sujobert, P., additional, Terriou, L., additional, Vinit, J., additional, Vinzio, S., additional, Weitten, T., additional, and Zhao, L.P., additional

Published
2023
Full Text
View/download PDF

13. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Author

Ruggeri, A., de Wreede, L. C., Muller, C. R., Crivello, P., Bonneville, E. F., Petersdorf, E. W., Socie, G., Dubois, V., Niittyvuopio, R., Perasaari, J., Yakoub-Agha, I., Cornelissen, J. J., Wieten, L., Gedde-Dahl, T., Forcade, E., Crawley, C. R., Marsh, S. G. E., Gandemer, V., Tholouli, E., Bulabois, C. -E., Huynh, A., Choi, G., Deconinck, E., Itala-Remes, M., Lenhoff, S., Bengtsson, M., Johansson, J. -E., van Gorkom, G., Hoogenboom, J. D., Vago, L., Rocha, V., Bonini, C., Chabannon, C., Fleischhauer, K., Clausen, J., Holter, W., Kalhs, P., Beguin, Y., Bron, D., Deeren, D., Lung, W. K., Kerre, T., Poire, X., Selleslag, D., Schroyens, W., Jindra, P., Mayer, J., Vydra, J., Zak, P., Nielsen, B., Sengeloev, H., Kaare, A., Partanen, A., Bay, J., Bertrand, Y., Blaise, D., Bourhis, J. H., Chevallier, P., Cluzeau, T., Damaj, G., Fegueux, N., Guyotat, D., Hunault-Berger, M., Labussiere-Wallet, H., Leleu, X., Lioure, B., Maury, S., Michel, G., Mohty, M., Rubio, M. T., Tilly, H., Turlure, P., Bethge, W., Casper, J., Einsele, H., Ganser, A., Kroger, N., Martin, S., Platzbecker, U., Reinhardt, C., Schafer-Eckart, K., Thurner, L., Valerius, T., Wulf, G. G., Karakasis, D., Spyridonidis, A., Hauser, P., Remenyi, P., Reykdal, S., Mousavi, A., Angelucci, E., Arcese, W., Benedetti, F., Bernasconi, P., Biondi, A., Bonifazi, F., Carella, A. M., Carluccio, P., Casini, M., Cavanna, L., Ciceri, F., Cimino, G., Corradini, P., Fanin, R., Galieni, P., Grillo, G., Iori, A. P., La Nasa, G., Locatelli, Franco, Marotta, G., Martino, M., Mazza, P., Mordini, N., Musso, M., Olivieri, A., Pavone, V., Pane, F., Petrini, M., Pioltelli, P., Rambaldi, A., Ruggeri, M., Saccardi, R., Santarone, S., Scime, R., Sica, S., Tarella, C., Velardi, A., Visani, G., Zecca, M., Tanase, A., Kulagin, A., Savchenko, V., Lopez, C. A., Amor, A. A., Lopez, J. L. B., Caballero, D., Duarte, R., Cascon, M. J. P., Porras, R. P., Perez-Simon, J. A., Rovira, M., Sanz, J., Carrete, J. P. T., Cammenga, J., Isaksson, C., Mielke, S., Chalandon, Y., Passweg, J., Schanz, U., Meijer, E., Kuball, J., Veelken, J. H., Apperley, J., Bloor, A., Byrne, J., Carpenter, B., Clark, A., Collin, M., Craddock, C., Gibson, B. E., Khan, A., Martin, M., Medd, P., Nicholson, E., Orchard, K., Patel, A., Peniket, A., Potter, V., Snowden, J., Wilson, K. M. O., Locatelli F. (ORCID:0000-0002-7976-3654), Ruggeri, A., de Wreede, L. C., Muller, C. R., Crivello, P., Bonneville, E. F., Petersdorf, E. W., Socie, G., Dubois, V., Niittyvuopio, R., Perasaari, J., Yakoub-Agha, I., Cornelissen, J. J., Wieten, L., Gedde-Dahl, T., Forcade, E., Crawley, C. R., Marsh, S. G. E., Gandemer, V., Tholouli, E., Bulabois, C. -E., Huynh, A., Choi, G., Deconinck, E., Itala-Remes, M., Lenhoff, S., Bengtsson, M., Johansson, J. -E., van Gorkom, G., Hoogenboom, J. D., Vago, L., Rocha, V., Bonini, C., Chabannon, C., Fleischhauer, K., Clausen, J., Holter, W., Kalhs, P., Beguin, Y., Bron, D., Deeren, D., Lung, W. K., Kerre, T., Poire, X., Selleslag, D., Schroyens, W., Jindra, P., Mayer, J., Vydra, J., Zak, P., Nielsen, B., Sengeloev, H., Kaare, A., Partanen, A., Bay, J., Bertrand, Y., Blaise, D., Bourhis, J. H., Chevallier, P., Cluzeau, T., Damaj, G., Fegueux, N., Guyotat, D., Hunault-Berger, M., Labussiere-Wallet, H., Leleu, X., Lioure, B., Maury, S., Michel, G., Mohty, M., Rubio, M. T., Tilly, H., Turlure, P., Bethge, W., Casper, J., Einsele, H., Ganser, A., Kroger, N., Martin, S., Platzbecker, U., Reinhardt, C., Schafer-Eckart, K., Thurner, L., Valerius, T., Wulf, G. G., Karakasis, D., Spyridonidis, A., Hauser, P., Remenyi, P., Reykdal, S., Mousavi, A., Angelucci, E., Arcese, W., Benedetti, F., Bernasconi, P., Biondi, A., Bonifazi, F., Carella, A. M., Carluccio, P., Casini, M., Cavanna, L., Ciceri, F., Cimino, G., Corradini, P., Fanin, R., Galieni, P., Grillo, G., Iori, A. P., La Nasa, G., Locatelli, Franco, Marotta, G., Martino, M., Mazza, P., Mordini, N., Musso, M., Olivieri, A., Pavone, V., Pane, F., Petrini, M., Pioltelli, P., Rambaldi, A., Ruggeri, M., Saccardi, R., Santarone, S., Scime, R., Sica, S., Tarella, C., Velardi, A., Visani, G., Zecca, M., Tanase, A., Kulagin, A., Savchenko, V., Lopez, C. A., Amor, A. A., Lopez, J. L. B., Caballero, D., Duarte, R., Cascon, M. J. P., Porras, R. P., Perez-Simon, J. A., Rovira, M., Sanz, J., Carrete, J. P. T., Cammenga, J., Isaksson, C., Mielke, S., Chalandon, Y., Passweg, J., Schanz, U., Meijer, E., Kuball, J., Veelken, J. H., Apperley, J., Bloor, A., Byrne, J., Carpenter, B., Clark, A., Collin, M., Craddock, C., Gibson, B. E., Khan, A., Martin, M., Medd, P., Nicholson, E., Orchard, K., Patel, A., Peniket, A., Potter, V., Snowden, J., Wilson, K. M. O., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

NO ABSTRACT

Published
2023

14. Towards the Computation of Stabilizing Controllers of Multidimensional Systems

Author

Cluzeau, T., Moroz, G., and Quadrat, A.

Abstract

In this paper, we further study the effective computation of stabilizing controllers of multidimensional systems. Within the algebraic analysis approach, the stabilization problem can be characterized by the fact that a certain finitely presented A-module M, naturally associated with the multidimensional system, is projective, where A denotes the ring of multivariate rational functions without poles in the closed complex unit polydisc Dn. This condition can be reduced to the existence of an element sof a polynomial ideal I which has no zero in Dn. According to the Polydisc Nullstellensatz, the latter condition is equivalent to the fact that no complex zero of the elements of I belongs to Dn. If this condition is satisfied, using cyclic resultants and linear programming, we then propose a method to compute such a polynomial s. Finally, using computer algebra methods for effectively handling basic operations on R[s-1]-modules, where R is a polynomial ring, we show how to compute stabilizing controllers.

Published
2024
Full Text
View/download PDF

18. P057 - Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION

Author

Rombaut, D., Lefevre, C., Farhat, B., Bondu, S., Letessier, A., Lesieur-Pasquier, A., Castillo-Guzman, D., Leduc, M., Hartono, S., Chesnais, V., Mangione, R., Boussaid, I., Houy, A., Bouscary, D., Willems, L., Chapuis, N., Kosmider, O., Park, S., Raynaud, S., Cluzeau, T., Clappier, E., Fenaux, P., Ades, L., Margueron, R., Wassef, M., Alsafadi, S., Solary, E., Constantinou, A., Stern, M.-H., Palancade, B., Droin, N., Miotto, B., Chédin, F., and Fontenay, M.

Published
2023
Full Text
View/download PDF

20. On exponential stability of a class of descriptor continuous linear 2D Roesser models.

Author

Bachelier, O., Cluzeau, T., Rigaud, A., Silva Alvarez, F. J., and Yeganefar, N.

Subjects
*LINEAR matrix inequalities, *EXPONENTIAL stability
Abstract

This article is dedicated to the exponential stability of a class of descriptor continuous Roesser 2D linear models. One of the two dimensions is privileged so that the exponential stability must be mainly understood as the vanishing propagation of the state vector along that dimension. This stability is analysed through a tractable test based upon Linear Matrix Inequalities (LMI). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI

Author

Cluzeau, T, Lambert, J, Raus, N, Dessaux, K, Absi, L, Delbos, F, Devys, A, De Matteis, M, Dubois, V, Filloux, M, Fort, M, Hau, F, Jollet, I, Labalette, M, Masson, D, Mercier, B, Pedron, B, Perrier, P, Picard, C, Quainon, F, Ramounau-Pigot, A, Renac, V, Van Endert, P, Charron, D, Peffault de la Tour, R, Taupin, J L, and Loiseau, P

Published
2016
Full Text
View/download PDF

23. S236: RANDOMIZED MULTICENTER PHASE III STUDY OF HAPLO VERSUS HLA-MATCHED UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS

Author

Harbi, S., primary, Boher, J.-M., additional, Forcade, E., additional, Chevallier, P., additional, Peffault De Latour, R., additional, Malard, F., additional, Francois, S., additional, Charbonnier, A., additional, Hermet, E., additional, Bulabois, C. E., additional, Huynh, A., additional, Berceanu, A., additional, Cluzeau, T., additional, Rubio, M. T., additional, Furst, S., additional, devillier, R., additional, Mohty, M., additional, and Blaise, D., additional

Published
2022
Full Text
View/download PDF

24. PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY

Author

Raffoux, E., primary, De Botton, S., additional, Ades, L., additional, Carré, M., additional, Cluzeau, T., additional, Saillard, C., additional, Heiblig, M., additional, Beckerich, F., additional, Gastaud, L., additional, Dupuis, A., additional, Richez, U., additional, and Dumas, P.-Y., additional

Published
2022
Full Text
View/download PDF

25. P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM

Author

Zeidan, A. M., primary, Al-Kali, A., additional, Borate, U., additional, Cluzeau, T., additional, DeZern, A. E., additional, Esteve, J., additional, Giagounidis, A., additional, Kobata, K., additional, Lyons, R., additional, Platzbecker, U., additional, Sallman, D. A., additional, Santini, V., additional, Sanz, G. F., additional, Sekeres, M. A., additional, Wei, A. H., additional, Xiao, Z., additional, Van Hoef, M., additional, Nourry-Boulot, C., additional, Sadek, I., additional, Ma, F., additional, Iordan, A., additional, Sabo, J., additional, and Garcia-Manero, G., additional

Published
2022
Full Text
View/download PDF

29. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III

Author

Cluzeau, T., primary, Sebert, M., additional, Rahmé, R., additional, Cuzzubbo, S., additional, Walter-Petrich, A., additional, Peterlin, P., additional, Recher, C., additional, Stamatoullas, A., additional, Willems, L., additional, Raffoux, E., additional, Berthon, C., additional, Sallman, D., additional, Ades, L., additional, and Fenaux, P., additional

Published
2021
Full Text
View/download PDF

30. Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III

Author

Peterlin, P., primary, Turlure, P., additional, Chevallier, P., additional, Gourin, M.-P., additional, Dumas, P.-Y., additional, Thepot, S., additional, Berceanu, A., additional, Park, S., additional, Hospital, M.-A., additional, Cluzeau, T., additional, Torregrossa-Diaz, J.-M., additional, Devron, L., additional, Sapena, R., additional, Chermat, F., additional, Dimicoli-Salazar, S., additional, and Fenaux, P., additional

Published
2021
Full Text
View/download PDF

31. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Author

Lin WY, Fordham SE, Hungate E, Sunter NJ, Elstob C, Xu Y, Park C, Quante A, Strauch K, Gieger C, Skol A, Rahman T, Sucheston-Campbell L, Wang J, Hahn T, Clay-Gilmour AI, Jones GL, Marr HJ, Jackson GH, Menne T, Collin M, Ivey A, Hills RK, Burnett AK, Russell NH, Fitzgibbon J, Larson RA, Le Beau MM, Stock W, Heidenreich O, Alharbi A, Allsup DJ, Houlston RS, Norden J, Dickinson AM, Douglas E, Lendrem C, Daly AK, Palm L, Piechocki K, Jeffries S, Bornhäuser M, Röllig C, Altmann H, Ruhnke L, Kunadt D, Wagenführ L, Cordell HJ, Darlay R, Andersen MK, Fontana MC, Martinelli G, Marconi G, Sanz MA, Cervera J, Gómez-Seguí I, Cluzeau T, Moreilhon C, Raynaud S, Sill H, Voso MT, Lo-Coco F, Dombret H, Cheok M, Preudhomme C, Gale RE, Linch D, Gaal-Wesinger J, Masszi A, Nowak D, Hofmann WK, Gilkes A, Porkka K, Milosevic Feenstra JD, Kralovics R, Grimwade D, Meggendorfer M, Haferlach T, Krizsán S, Bödör C, Stölzel F, Onel K, and Allan JM

Subjects
RISK, HLA, OLDER PATIENTS, AML, hemic and lymphatic diseases, HUMAN-LEUKOCYTE ANTIGEN, HIF-1-ALPHA, IMMUNE ESCAPE, CLONAL EVOLUTION, CANCER, GENE-MUTATIONS
Abstract

Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we perform a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorporating a total of 4018 AML cases and 10488 controls. We identify a genome-wide significant risk locus for AML at 11q13.2 (rs4930561; P = 2.15 × 10 -8 ; KMT5B). We also identify a genome-wide significant risk locus for the cytogenetically normal AML sub-group (N = 1287) at 6p21.32 (rs3916765; P = 1.51 × 10 -10 ; HLA). Our results inform on AML etiology and identify putative functional genes operating in histone methylation (KMT5B) and immune function (HLA).

Published
2021

38. Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis

Author

Robin, M., Chevret, S. (Sylvie), Koster, L. (Linda), Wolschke, C., Yakoub-Agha, I. (I.), Bourhis, J. H., Chevallier, P. (Patrice), Cornelissen, J.J. (Jan), Remenyi, P., Maertens, J. (Johan), Poire, X, Craddock, C.F. (Charles), Socie, G. (Gerard), Itala-Remes, M., Schouten, HC, Marchand, T., Passweg, J, Blaise, D. (Didier), Damaj, G., Ozkurt, Z.N., Zuckerman, T., Cluzeau, T., Labussiere-Wallet, H., Cammenga, J. (Jörg), McLornan, D., Chalandon, Y. (Yves), Kröger, N. (Nicolaus), Robin, M., Chevret, S. (Sylvie), Koster, L. (Linda), Wolschke, C., Yakoub-Agha, I. (I.), Bourhis, J. H., Chevallier, P. (Patrice), Cornelissen, J.J. (Jan), Remenyi, P., Maertens, J. (Johan), Poire, X, Craddock, C.F. (Charles), Socie, G. (Gerard), Itala-Remes, M., Schouten, HC, Marchand, T., Passweg, J, Blaise, D. (Didier), Damaj, G., Ozkurt, Z.N., Zuckerman, T., Cluzeau, T., Labussiere-Wallet, H., Cammenga, J. (Jörg), McLornan, D., Chalandon, Y. (Yves), and Kröger, N. (Nicolaus)

Abstract

The use of antihuman T-lymphocyte immunoglobulin in the setting of transplantation from an HLA-matched related donor is still much debated. Acute and chronic graft-versus-host disease are the main causes of morbidity and mortality after allogeneic hematopoietic st

Published
2019
Full Text
View/download PDF

39. Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis

Author

Robin, M, Chevret, S, Koster, L, Wolschke, C, Yakoub-Agha, I, Bourhis, J H, Chevallier, P, Cornelissen, Jan, Remenyi, P, Maertens, J, Poire, X, Craddock, C, Socie, G, Itala-Remes, M, Schouten, HC, Marchand, T, Passweg, J, Blaise, D, Damaj, G, Ozkurt, ZN, Zuckerman, T, Cluzeau, T, Labussiere-Wallet, H, Cammenga, J, McLornan, D, Chalandon, Y, Kroger, N, Robin, M, Chevret, S, Koster, L, Wolschke, C, Yakoub-Agha, I, Bourhis, J H, Chevallier, P, Cornelissen, Jan, Remenyi, P, Maertens, J, Poire, X, Craddock, C, Socie, G, Itala-Remes, M, Schouten, HC, Marchand, T, Passweg, J, Blaise, D, Damaj, G, Ozkurt, ZN, Zuckerman, T, Cluzeau, T, Labussiere-Wallet, H, Cammenga, J, McLornan, D, Chalandon, Y, and Kroger, N

Published
2019

40. PF211 MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL

Author

Dal Bello, R., primary, Adès, L., additional, Braun, T., additional, Pasanisi, J., additional, Fournier, E., additional, Bérthon, C., additional, Clappier, E., additional, Raffoux, E., additional, Lebon, D., additional, Cluzeau, T., additional, Roumier, C., additional, Plesa, A., additional, Celli Lebras, K., additional, Dombret, H., additional, Preudhomme, C., additional, Puissant, A., additional, Gardin, C., additional, and Itzykson, R., additional

Published
2019
Full Text
View/download PDF

41. PF263 DEEP RESPONSE AFTER CPX-351 TREATMENT IN T-AML AND MRC-AML: A REPORT FROM A MULTICENTRIC FRENCH COHORT

Author

Chiche, E., primary, Bertoli, S., additional, Recher, C., additional, Thomas, X., additional, Loschi, M., additional, Bonmati, C., additional, Roth-Guepin, G., additional, Peterlin, P., additional, Chevallier, P., additional, Lejeune, C., additional, Sauvezie, M., additional, Pigneux, A., additional, Sebert, M., additional, Ades, L., additional, and Cluzeau, T., additional

Published
2019
Full Text
View/download PDF

42. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Author

Stahl, M., DeVeaux, M., Witte, T.J. de, Neukirchen, J., Sekeres, M.A., Brunner, A.M., Roboz, G.J., Steensma, D.P., Bhatt, V.R., Platzbecker, U., Cluzeau, T., Prata, P.H., Itzykson, R., Fenaux, P., Fathi, A.T., Smith, A., Germing, U., Ritchie, E.K., Verma, V., Nazha, A., Maciejewski, J.P., Podoltsev, N.A., Prebet, T., Santini, V., Gore, S.D., Komrokji, R.S., Zeidan, A.M., Stahl, M., DeVeaux, M., Witte, T.J. de, Neukirchen, J., Sekeres, M.A., Brunner, A.M., Roboz, G.J., Steensma, D.P., Bhatt, V.R., Platzbecker, U., Cluzeau, T., Prata, P.H., Itzykson, R., Fenaux, P., Fathi, A.T., Smith, A., Germing, U., Ritchie, E.K., Verma, V., Nazha, A., Maciejewski, J.P., Podoltsev, N.A., Prebet, T., Santini, V., Gore, S.D., Komrokji, R.S., and Zeidan, A.M.

Abstract

Item does not contain fulltext, Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are limited by small numbers and their single-center nature, and report conflicting data regarding predictors for response to IST. We examined outcomes associated with IST and predictors of benefit in a large international cohort of patients with MDS. Data were collected from 15 centers in the United States and Europe. Responses, including red blood cell (RBC) transfusion independence (TI), were assessed based on the 2006 MDS International Working Group criteria, and overall survival (OS) was estimated by Kaplan-Meier methods. Logistic regression models estimated odds for response and TI, and Cox Proportional Hazard models estimated hazards ratios for OS. We identified 207 patients with MDS receiving IST, excluding steroid monotherapy. The most common IST regimen was anti-thymocyte globulin (ATG) plus prednisone (43%). Overall response rate (ORR) was 48.8%, including 11.2% (95% confidence interval [CI], 6.5%-18.4%) who achieved a complete remission and 30% (95% CI, 22.3%-39.5%) who achieved RBC TI. Median OS was 47.4 months (95% CI, 37-72.3 months) and was longer for patients who achieved a response or TI. Achievement of RBC TI was associated with a hypocellular bone marrow (cellularity < 20%); horse ATG plus cyclosporine was more effective than rabbit ATG or ATG without cyclosporine. Age, transfusion dependence, presence of paroxysmal nocturnal hemoglobinuria or large granular lymphocyte clones, and HLA DR15 positivity did not predict response to IST. IST leads to objective responses in nearly half the selected patients with the highest rate of RBC TI achieved in patients with hypocellular bone marrows.

Published
2018

45. Evaluation of Salvage Induction Chemotherapy Regimens in Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure

Author

Ball, B., primary, Komrokji, R., additional, Adès, L., additional, Sekeres, M., additional, DeZern, A., additional, Pleyer, L., additional, Vey, N., additional, Almeida, A., additional, Germing, U., additional, Cluzeau, T., additional, Platzbecker, U., additional, Gore, S., additional, Fenaux, P., additional, and Prebet, T., additional

Published
2017
Full Text
View/download PDF

46. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

Author

Ramos F., Maurillo L., Itzykson R., Bargay J., Stauder R., Venditti A., Seegers V., Gaidano G., Gardin C., Musto P., Greil R., Sánchez-Guijo F., Fenaux P., Thépot S., Récher C., Raffoux E., Quesnel B., Delaunay J., Cluzeau T., Koka A.M., Stamatoullas A., Chaury M.-P., Gyan E., Cheze S., Banos A., Morel P., Plantier I., Taksin A.-L., Shanti A., Sanhes L., De Botton S., Marolleau J.P., Pautas C., Wattel E., Isnard F., Guerci A., Vey N., Dreyfus F., Ifrah N., Ades L., Martínez-Robles V., Debén G., Garrido A., Casaño J., Salamero O., Bergua J.M., Colado E., García R., Pedro C., Redondo S., Tormo M., Bonanad S., Díez-Campelo M., Pérez-Encinas M., de la Fuente A., Xicoy B., Falantes J.F., Font P., González-López T.J., Martín-Núñez G., Montesinos P., Pleyer L., Burgstaller S., Schreder M., Tinchon C., Pfeilstoecker M., Steinkirchner S., Melchardt T., Mitrovic M., Girschikofsky M., Lang A., Krippl P., Sliwa T., Egle A., Linkesch W., Voskova D., Angermann H., Spagnoli A., Lunghi M., Pietrantuono G., and Villani O.

Subjects
blood toxicity, cancer patient, leukocyte count, very elderly, retrospective study, blast cell, ear disease, cytogenetics, middle aged, neurotoxicity, Leukemia, antineoplastic antimetabolite, Aged, 80 and over, adult, nephrotoxicity, European ALMA score, clinical trial, acute granulocytic leukemia, aged, Leukemia, Myeloid, Acute, female, Italy, priority journal, validation study, drug withdrawal, Azacitidine, France, survival rate, Antimetabolites, Antineoplastic, overall survival, cardiotoxicity, Article, eye toxicity, multiple cycle treatment, remission, male, follow up, Humans, controlled study, drug fatality, human, gastrointestinal toxicity, survival time, lung toxicity, human cell, practice guideline, Australia, scoring system, treatment response, hearing impairment, major clinical study, skin toxicity, mortality, infection, multicenter study, Spain, treatment outcome, population research, musculoskeletal disease, Follow-Up Studies
Abstract

Hypomethylating agents are able to prolong the overall survival of some patients diagnosed with acute myeloid leukemia. The aim of this study was to evaluate the clinical use of azacitidine as front-line therapy in unfit acute myeloid leukemia (AML) patients and to develop a clinical prediction model to identify which patients may benefit more from the drug. One hundred and ten untreated unfit AML patients received front-line azacitidine therapy in Spain, and response and survival were evaluated in them following European LeukemiaNet (ELN) guidelines. A clinical prediction rule was obtained from this population that was validated and refined in 261 patients treated in France, Austria and Italy. ELN response was achieved in 21.0% of the 371 patients (CI95% 17.0-25.5) and did not depend on bone marrow blast cell percentage. Median overall survival was 9.6 months (CI95% 8.5-10.8) and 40.6% of the patients were alive at 1 year (CI95% 35.5-45.7). European ALMA score (E-ALMA), based on performance status, white blood cell counts at azacitidine onset and cytogenetics, discriminated three risk groups with different survival and response rates. Azacitidine seems a reasonable therapeutic option for most unfit AML patients, i.e. those displaying a favorable or intermediate E-ALMA score. © 2014 Elsevier Ltd.

Published
2015

48. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

Author

Sallman, D A, primary, Komrokji, R, additional, Vaupel, C, additional, Cluzeau, T, additional, Geyer, S M, additional, McGraw, K L, additional, Al Ali, N H, additional, Lancet, J, additional, McGinniss, M J, additional, Nahas, S, additional, Smith, A E, additional, Kulasekararaj, A, additional, Mufti, G, additional, List, A, additional, Hall, J, additional, and Padron, E, additional

Published
2015
Full Text
View/download PDF

49. 50 BCL2L10-POSITIVE CELL (BPC) QUANTIFICATION IS A PREDICTIVE FACTOR OF SURVIVAL IN AZA-TREATED HIGHER RISK MDS (HR-MDS) AND AML

Author

Cluzeau, T., primary, Vidal, V., additional, Ginet, C., additional, Karsenti, J.M., additional, Luciano, F., additional, Gastaud, L., additional, Garnier, G., additional, Braun, T., additional, Hirsch, P., additional, Raffoux, E., additional, Nloga, A.M., additional, Dombret, H., additional, Rorhlich, P., additional, Ades, L., additional, Chomienne, C., additional, Auberger, P., additional, Robert, G., additional, and Fenaux, P., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results